Xiaoyan Pan

Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications

Targeted FcRn to deliver epitope-optimized RBD confers broad-spectrum mucosal protection against SARS-CoV-2.

Targeted FcRn to deliver epitope-optimized RBD confers broad-spectrum mucosal protection against SARS-CoV-2.

Journal: Molecular therapy. Nucleic acids
Published: March 27, 2026

Fulminant cardiovascular collapse after acute pancreatitis: a case report of non-alcoholic Shoshin beriberi and literature review.

Fulminant cardiovascular collapse after acute pancreatitis: a case report of non-alcoholic Shoshin beriberi and literature review.

Journal: AME case reports
Published: December 06, 2025

Universal broad-spectrum mucosal vaccine design for human coronaviruses inspired by artificial antibodies.

Universal broad-spectrum mucosal vaccine design for human coronaviruses inspired by artificial antibodies.

Journal: NPJ vaccines
Published: August 31, 2025

Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Journal: NPJ vaccines
Published: July 10, 2025

Salvianolic acid A from Salvia miltiorrhiza identified as a cap-dependent endonuclease inhibitor for pathogenic arenaviruses.

Salvianolic acid A from Salvia miltiorrhiza identified as a cap-dependent endonuclease inhibitor for pathogenic arenaviruses.

Journal: Acta pharmacologica Sinica
Published: April 14, 2025

Eltrombopag, an FDA-approved drug, inhibits dengue virus type 2 by targeting NS2B-NS3 protease.

Eltrombopag, an FDA-approved drug, inhibits dengue virus type 2 by targeting NS2B-NS3 protease.

Journal: Virologica Sinica
Published: February 19, 2025

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters.

Journal: NPJ vaccines
Published: February 08, 2025

Identification of Licoflavone C as a cap-dependent endonuclease inhibitor against severe fever with thrombocytopenia syndrome virus.

Identification of Licoflavone C as a cap-dependent endonuclease inhibitor against severe fever with thrombocytopenia syndrome virus.

Journal: Acta pharmacologica Sinica
Published: November 11, 2024

A hTfR1 Receptor-Specific VHH Antibody Neutralizes Pseudoviruses Expressing Glycoproteins from Junín and Machupo Viruses.

A hTfR1 Receptor-Specific VHH Antibody Neutralizes Pseudoviruses Expressing Glycoproteins from Junín and Machupo Viruses.

Journal: Viruses
Published: October 23, 2024

Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.

Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV.

Journal: NPJ vaccines
Published: September 10, 2024

Diagnostic and Prognostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) for Septic Cardiomyopathy.

Diagnostic and Prognostic Value of Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) for Septic Cardiomyopathy.

Journal: Journal of inflammation research
Published: June 07, 2024

A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.

A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.

Journal: Journal of virology
Published: June 03, 2024
Showing 1-12 of 45

Last Updated: 09/26/2026